A

Adaptive Biotechnologies Corp
D

ADPT

25.620
USD
0.34
(1.34%)
قبل الجلسة·25.400USD-0.220(-0.86%)
حجم التداول
85,425
الربح لكل سهم
-1
العائد الربحي
-
P/E
-64
حجم السوق
4,088,845,472
نظرة عامة
أصول ذات صلة
ABBV
ABBV
D
شركة أب في
283.66
9.37(3.42%)
277.69-5.97(-2.10%)
AMGN
AMGN
D
Amgen
426.14
13.26(3.21%)
418.63-7.51(-1.76%)
BMY
BMY
D
Bristol-Myers Squibb Co
59.270
2.570(4.53%)
56.930-2.340(-3.95%)
GILD
GILD
D
Gilead Sciences
153.600
5.720(3.87%)
149.000-4.600(-2.99%)
JNJ
JNJ
D
جونسون آند جونسون
253.940
5.330(2.14%)
248.610-5.330(-2.10%)
LLY
LLY
D
ايلاي ليلي وشركاءه
1,211.40
44.62(3.82%)
1,181.01-30.39(-2.51%)
MRK
MRK
D
ميرك اند كو
147.365
5.385(3.79%)
143.150-4.215(-2.86%)
NVS
NVS
D
نوفارتس AG
146.910
4.550(3.20%)
144.290-2.620(-1.78%)
PFE
PFE
D
فايزر
29.225
0.845(2.98%)
28.630-0.595(-2.04%)
SNY
SNY
D
Sanofi ADS
39.760
0.655(1.68%)
39.360-0.400(-1.01%)
المزيد

العنوان: Adaptive Biotechnologies Corp

القطاع: الرعاية الصحية
الصناعة: Diagnostics & Research
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product,clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.